Biblio Discovery — Demo Discovery Service

15 hasil untuk "Shanu Modi"

Menampilkan 1–15 · 0,17 detik · RSS

  1. Artikel Jurnal

    HER2 breast cancer therapies: a review

    Conleth G Murphy; Shanu Modi

    Biologics: Targets & Therapy, Vol. 2009 No. default · 2009 · Inggris · DOAJ Scopus

    Conleth G Murphy, Shanu ModiBreast Cancer Medicine Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USAAbstract: Amplification of the HER2 gene and/or overexpression of its protein product have been found in up to 25% to 30% of human breast cancers and have…

  2. Artikel Jurnal

    Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions

    Emanuela Ferraro; Joshua Z. Drago; Shanu Modi

    Breast Cancer Research, Vol. 23 No. 1 · 2021 · Inggris · DOAJ Scopus

    Abstract The development of anti-HER2 agents has been one of the most meaningful advancements in the management of metastatic breast cancer, significantly improving survival outcomes. Despite the efficacy of anti-HER2 monoclonal antibodies, concurrent chemotherapy is still needed to maximize…

  3. Artikel Jurnal

    Multifocal and pathologically-confirmed brain metastasis complete response to trastuzumab deruxtecan

    Nelson S Moss; Umberto Tosi; Bianca D Santomasso dkk.

    CNS Oncology, Vol. 11 No. 3 · 2022 · Inggris · DOAJ Scopus

    Antibody–drug conjugates have transformed the treatment of HER2+ breast and other cancers. Unfortunately, the CNS remains a sanctuary site for many such patients in part due to poor macromolecule penetration across the blood–brain tumor barrier. Trastuzumab deruxtecan (T-DXd), a high-payload…

  4. Artikel Jurnal

    Real-world treatment patterns and outcomes in HER2-low, HR+ metastatic breast cancer patients previously treated with endocrine therapy in the United States

    Shanu Modi; Danalyn Byng; Suyuan Zhang dkk.

    Breast, Vol. 86 · 2026 · Inggris · DOAJ Scopus

    Background: Up to 60% of metastatic breast cancer (mBC) cases historically classified as human epidermal growth factor receptor 2 (HER2)-negative may be HER2-low, expanding options towards new HER2 targeted treatments. Greater understanding of the current therapeutic journey of this population can…

  5. Artikel Jurnal

    Targeting HER2-low in metastatic breast cancer: an evolving treatment paradigm

    Charlie Yang; Christine Brezden-Masley; Anil Abraham Joy dkk.

    Therapeutic Advances in Medical Oncology, Vol. 15 · 2023 · Inggris · DOAJ Scopus

    The results of the Phase III DESTINY-Breast04 trial of trastuzumab deruxtecan (T-DXd) are leading to a shift in both the classification and treatment of human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer. In this trial, T-DXd was associated with a substantial survival…

  6. Artikel Jurnal

    Incidence of HER2-expressing brain metastases in patients with HER2-null breast cancer: a matched case analysis

    Nelson S. Moss; Jolene M. Singh; Anne S. Reiner dkk.

    npj Breast Cancer, Vol. 9 No. 1 · 2023 · Inggris · DOAJ Scopus

    Abstract The HER2-directed antibody-drug conjugate trastuzumab deruxtecan is active against lower levels of HER2 expression than prior-generation therapies. The rate of HER2 expression in brain metastases among patients with initially HER2-null breast cancer is undefined, and receptor discordance…

  7. Artikel Jurnal

    A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer

    Komal Jhaveri; Rui Wang; Eleonora Teplinsky dkk.

    Breast Cancer Research, Vol. 19 No. 1 · 2017 · Inggris · DOAJ Scopus

    Abstract Background Targeted therapies in HER2-positive metastatic breast cancer significantly improve outcomes but efficacy is limited by therapeutic resistance. HER2 is an acutely sensitive Heat Shock Protein 90 (HSP90) client and HSP90 inhibition can overcome trastuzumab resistance. Preclinical…

  8. Artikel Jurnal

    Predictors of response to CDK4/6i retrial after prior CDK4/6i failure in ER+ metastatic breast cancer

    Nicholas Mai; Carlos H. dos Anjos; Pedram Razavi dkk.

    npj Breast Cancer, Vol. 10 No. 1 · 2024 · Inggris · DOAJ Scopus

    Abstract After disease progression on endocrine therapy (ET) plus a CDK4/6 inhibitor, there is no standardized sequence for subsequent treatment lines for estrogen receptor positive (ER+) metastatic breast cancer (MBC). CDK4/6i retrial as a treatment strategy is commonplace in modern clinical…

  9. Artikel Jurnal

    Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab

    Emanuela Ferraro; Jasmeet Singh; Sujata Patil dkk.

    npj Breast Cancer, Vol. 8 No. 1 · 2022 · Inggris · DOAJ Scopus

    Abstract The addition of pertuzumab (P) to trastuzumab (H) and neoadjuvant chemotherapy (NAC) has decreased the risk of distant recurrence in early stage HER2-positive breast cancer. The incidence of brain metastases (BM) in patients who achieved pathological complete response (pCR) versus those…

  10. Artikel Jurnal

    Brain radiotherapy, tremelimumab-mediated CTLA-4-directed blockade +/− trastuzumab in patients with breast cancer brain metastases

    David B. Page; Kathryn Beal; Stefanie N. Linch dkk.

    npj Breast Cancer, Vol. 8 No. 1 · 2022 · Inggris · DOAJ Scopus

    Abstract Breast cancer brain metastases (BCBM) are a common and devastating complication of metastatic breast cancer with conventional systemic therapies demonstrating limited effectiveness. Consequently, radiotherapy (RT) ± surgery remains the cornerstone of BCBM management. Because preclinical…

  11. Artikel Jurnal

    Local Therapy for Isolated Central Nervous System Progression Among Patients Receiving Antibody-Drug Conjugate Therapy

    Emily S. Lebow, MD; Jordan Eichholz, MS; Zhigang Zhang, PhD dkk.

    Advances in Radiation Oncology, Vol. 10 No. 3 · 2025 · Inggris · DOAJ Scopus

    Purpose: Antibody drug conjugates (ADCs) are an increasingly important class of therapeutics among patients with breast, lung, urothelial, and other malignancies. Guidelines recommend local therapy and continuation of current systemic therapy among patients with isolated brain relapse. We describe…

  12. Artikel Jurnal

    Molecular Stressors Engender Protein Connectivity Dysfunction through Aberrant N-Glycosylation of a Chaperone

    Pengrong Yan; Hardik J. Patel; Sahil Sharma dkk.

    Cell Reports, Vol. 31 No. 13 · 2020 · Inggris · DOAJ Scopus

    Summary: Stresses associated with disease may pathologically remodel the proteome by both increasing interaction strength and altering interaction partners, resulting in proteome-wide connectivity dysfunctions. Chaperones play an important role in these alterations, but how these changes are…

  13. Artikel Jurnal

    The HER2-directed antibody-drug conjugate DHES0815A in advanced and/or metastatic breast cancer: preclinical characterization and phase 1 trial results

    Gail D. Lewis; Guangmin Li; Jun Guo dkk.

    Nature Communications, Vol. 15 No. 1 · 2024 · Inggris · DOAJ Scopus

    Abstract Approved antibody-drug conjugates (ADCs) for HER2-positive breast cancer include trastuzumab emtansine and trastuzumab deruxtecan. To develop a differentiated HER2 ADC, we chose an antibody that does not compete with trastuzumab or pertuzumab for binding, conjugated to a reduced potency…

  14. Artikel Jurnal

    Systems-level analyses of protein-protein interaction network dysfunctions via epichaperomics identify cancer-specific mechanisms of stress adaptation

    Anna Rodina; Chao Xu; Chander S. Digwal dkk.

    Nature Communications, Vol. 14 No. 1 · 2023 · Inggris · DOAJ Scopus

    Abstract Systems-level assessments of protein-protein interaction (PPI) network dysfunctions are currently out-of-reach because approaches enabling proteome-wide identification, analysis, and modulation of context-specific PPI changes in native (unengineered) cells and tissues are lacking. Herein…

  15. Artikel Jurnal

    Phosphorylation-driven epichaperome assembly is a regulator of cellular adaptability and proliferation

    Tanaya Roychowdhury; Seth W. McNutt; Chiranjeevi Pasala dkk.

    Nature Communications, Vol. 15 No. 1 · 2024 · Inggris · DOAJ Scopus

    Abstract The intricate network of protein-chaperone interactions is crucial for maintaining cellular function. Recent discoveries have unveiled the existence of specialized chaperone assemblies, known as epichaperomes, which serve as scaffolding platforms that orchestrate the reconfiguration of…